AI-generated summary
The authors randomized 93 older adults with mild cognitive impairment to transcranial photobiomodulation or placebo and reported 76 completers. The t-PBM group showed greater improvement on the Montreal Cognitive Assessment and higher serum BDNF levels, persisting to follow-up. Depression, anxiety, resilience and neurodegeneration markers did not differ.
- Participants
- 93
- Who or what was studied
- Older adults aged over 50 with mild cognitive impairment
- Limits stated in the abstract
- The abstract reports 76 of 93 participants completed the study, and the wavelength used is not stated.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Mild cognitive impairment, Transcranial photobiomodulation, Placebo-controlled, Montreal Cognitive Assessment, Near-infrared, Neuroplasticity, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.